C difficile risk
Oral Bioavailability


0 - 2 kg2+ kgIV/IM 50mg/kg/DOSE q12hIV/IM 50mg/kg/DOSE q8-12h.

0 - 2 kg2+ kgIV/IM 50mg/kg/DOSE q8-12hIV/IM 50mg/kg/DOSE q8h

IV/IM 100-150mg/kg/DAY divided q8h.
Max: 6g/dayCystic Fibrosis: IV 150-200mg/kg/DAY (up to 400mg/kg/DAY) divided q6-8h
Max: 12g/day.

Renally cleared, requires dosage adjustment with changes in renal function. Consult a pharmacist for renal dosing.

General Information

Broad gram negative coverage including Pseudomonas, generally used for nosocomial infections including post-neurosurgical meningitis, or other infections based on susceptibilities.

Notable lack of gram positive activity versus other cephalosporins

Allergy (immediate and delayed)- note potential cross-reactivity with aztreonam based on side chain

Antimicrobial class: 3rd generation Cephalosporin

Average serum half life:

  • neonates <23 days: 2.2-4.7 hours

  • adults: 1-2 hours

Route of Elimination: by glomerular filtration with 80-90% of dose excreted as unchanged drug in urine within 24 hours.